Scisparc Ltd (SPRC)

Name: Scisparc Ltd (SPRC) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Scisparc Ltd (SPRC)

Stock Card

$6.63

$0.05 (0.76%)

As on 31-Aug-2026 16:27EDT

Market cap

$152 Mln

Revenue (TTM)

$-- Mln

P/E Ratio

0.1

P/B Ratio

0.9

Div. Yield

0 %

Value Research Rating

Quality Score

Growth Score

Valuation Score

Momentum Score

Know more

Explore 5 star rated stocks

Scisparc (SPRC) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 6.50 High: 6.88

52 Week Range

Low: 2.98 High: 80.10

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$-- Mln
ROE

-1.8 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

1.2
Debt to Equity

0.1
Book Value

$73.3
EPS

$-210.7
Face value

--
Shares outstanding

23,073,243

10 Years Aggregate

CFO

$-44.27 Mln

EBITDA

$-46.71 Mln

Net Profit

$-43.52 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Scisparc (SPRC)	-45.8	-23.8	-32.4	-70.1	-79.2	-80.3	--
BSE Sensex	-9.1	-1.2	2.9	-3.6	5.7	6.2	10.5
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 31-Aug-2026 | #As on 26-Oct-2023

Company	2025	2023
Scisparc (SPRC)	-82.0	-75.2
S&P Small-Cap 600	4.0	13.9
BSE Sensex	9.1	18.7

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Peers

View Details

Company	Price ($)	Market Cap ($ Mln)	Revenue (TTM)	Net Profit (TTM)	OPM (%)	ROE (%)	P/E	P/B
Scisparc (SPRC)	6.6	151.8	0.9	-12.2	--	-196.5	0.1	0.9
Kamada - ADR	8.2	478.3	191.9	22.3	13.9	8.3	21.8	1.8
MediWound - ADR	12.6	163.4	11.9	-20.2	-176.1	-50.9	--	4.8
PainreformÂ (PRFX)	1.0	2.9	0.0	-4.8	--	-93.3	--	0.4
PolyPid (PYPD)	5.1	103.0	0.0	-31.5	--	-385.1	--	19.2

Shareholding Pattern

View Details

About Scisparc (SPRC)

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-210 for the... treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company sells hemp seed oil-based products and others. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and palmitoylethanolamide oral tablets CannAmide in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel. Read more

CEO & CFO

Mr. Oz Adler CPA
President & Director

Mr. Itschak Shrem
Headquarters

Tel Aviv-Yafo
Website

https://scisparc.com

FAQs for Scisparc (SPRC)

What is the current share price of Scisparc Ltd (SPRC) Today?

The share price of Scisparc Ltd (SPRC) is $6.63 (NASDAQ) as of 31-Aug-2026 16:27 EDT. Scisparc Ltd (SPRC) has given a return of -79.25% in the last 3 years.